McInnes G T, Lawson D H, Jick H
Ann Rheum Dis. 1981 Jun;40(3):245-9. doi: 10.1136/ard.40.3.245.
Of 29 524 hospitalised medical patients monitored in a drug surveillance programme 1835 (6.2%) received the xanthine oxidase inhibitor allopurinol. After the exclusion of skin reactions adverse effects were attributed to this drug in 33 (1.8%) patients, the most frequent being haematological abnormalities (11 patients, 0.6%) and diarrhoea and drug fever (5 each, 0.3%). Adverse effects were dose-related. Reactions were unrelated to age, weight, reason for therapy, admission blood urea, or albumin concentrations. Acute exacerbation of gout was troublesome in 3 patients (1 in 600 exposed).
在一项药物监测计划中，对29524名住院内科患者进行了监测，其中1835名（6.2%）接受了黄嘌呤氧化酶抑制剂别嘌醇。排除皮肤反应后，33名（1.8%）患者的不良反应归因于该药物，最常见的是血液学异常（11名患者，0.6%）以及腹泻和药物热（各5名，0.3%）。不良反应与剂量相关。反应与年龄、体重、治疗原因、入院时血尿素或白蛋白浓度无关。3名患者（每600名暴露者中有1名）出现痛风急性加重，令人困扰。
